Srs Capital Advisors, Inc. Mereo Biopharma Group PLC Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 4,000 shares of MREO stock, worth $7,280. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,000
Previous 4,000
-0.0%
Holding current value
$7,280
Previous $10,000
30.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MREO
# of Institutions
94Shares Held
94.3MCall Options Held
2.23MPut Options Held
179K-
Janus Henderson Group PLC London, X016.3MShares$29.6 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$27.9 Million0.5% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.44MShares$17.2 Million0.79% of portfolio
-
Mangrove Partners New York, NY7.79MShares$14.2 Million1.99% of portfolio
-
683 Capital Management, LLC New York, NY4.88MShares$8.87 Million0.57% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $227M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...